Onward Therapeutics licensed the exclusive worldwide rights of development, manufacture, and commercialization of OT-A201 from Biomunex Pharmaceuticals (Biomunex), a biopharmaceutical company discovering and developing bi- and multi-specific antibodies, in February 2021. The two companies agreed to co-develop this bispecific antibody until the completion of the phase 1 study in one of the indications. OT-A201 is a first-in-class humanized bispecific antibody targeting two immune checkpoints. With the potential synergistic anti-cancer effects, it is being evaluated as a new treatment for advanced haematological malignancies and solid tumors.
